Collaborations and business development are integral to our growth strategy and have played a key role in our complex generics and biosimilars business.
Momenta has two major complex generic collaborations with Sandoz, a division of Novartis.
In January 2016, Momenta entered into a broad global collaboration with Mylan for the development, manufacture and commercialization of six of Momenta’s biosimilar candidates. In October 2018, as part of a corporate restructuring, Momenta initiated discussions with Mylan to exit its participation in the development of its other biosimilar programs including M834, a proposed biosimilar to ORENCIA®. Momenta intends to focus solely on the continued development of M710.
In January 2017, Momenta entered into an exclusive research collaboration and worldwide license agreement with CSL to develop and commercialize Fc multimer proteins, including M230, a selective immunomodulator of Fc receptors. In addition to advancing M230, CSL and Momenta will collaborate to develop additional Fc multimer proteins that may originate from Momenta's or CSL's research.
Momenta is currently pursuing development or commercial stage collaborations in the following areas:
If you are interested in pursuing a collaboration opportunity with Momenta Pharmaceuticals, or have a technology you wish to introduce to our team, we welcome you to contact us at firstname.lastname@example.org.
LOVENOX® is a registered trademark of Sanofi-Aventis. COPAXONE® is a registered trademark of Teva Pharmaceutical Industries Ltd. Glatopa® is a trademark of Novartis AG.
Last Updated 4/14/2017